myeloproliferative neoplasms (MPN) | Page 30 | Aplastic Anemia & MDS International Foundation Return to top.

myeloproliferative neoplasms (MPN)

B. Douglas Smith, MD

Smith, B. Douglas
Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

B. Douglas Smith is Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York.  At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies. 

Michael Keng, MD

Keng, Michael
Assistant Professor, Division of Hematology/Oncology
University of Virginia Cancer Center

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital.

Erica Warlick, MD

Warlick, Erica
Assistant Professor of Medicine
University of Minnesota Medical Center

Dr. Warlick is an Assistant Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Her clinical and research efforts focus on the treatment of hematologic malignancies. She has particular interest in myeloid malignancies and the development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases.

Maria Baer, MD

Baer, Maria
Director, Hematologic Malignancies Program
University of Maryland Greenebaum Comprehensive Cancer Center

Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.

Richard M. Stone, MD

Stone, Richard M
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute

Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide.

How long do I have to live?

How long do I have to live?

This is most people’s first question, along with “what can I expect to happen.” The doctor’s answer is called a prognosis (an educated guess about the likely course of your disease and how long you might live). Because each person is unique, and each person’s disease is different, a prognosis can be difficult to make. Also, how a disease progresses over time is unpredictable, and less is known about rare diseases than common diseases.

Share with addtoany.com.